Biofil Chemicals and Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Biofil Chemicals and Pharmaceuticals has a total shareholder equity of ₹176.7M and total debt of ₹5.6M, which brings its debt-to-equity ratio to 3.2%. Its total assets and total liabilities are ₹422.2M and ₹245.5M respectively. Biofil Chemicals and Pharmaceuticals's EBIT is ₹9.4M making its interest coverage ratio 33.2. It has cash and short-term investments of ₹575.0K.
Key information
3.2%
Debt to equity ratio
₹5.64m
Debt
Interest coverage ratio | 33.2x |
Cash | ₹575.00k |
Equity | ₹176.70m |
Total liabilities | ₹245.46m |
Total assets | ₹422.16m |
Recent financial health updates
No updates
Recent updates
Biofil Chemicals and Pharmaceuticals Limited's (NSE:BIOFILCHEM) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 01Biofil Chemicals and Pharmaceuticals Limited's (NSE:BIOFILCHEM) Shares Climb 60% But Its Business Is Yet to Catch Up
Sep 18There's Reason For Concern Over Biofil Chemicals and Pharmaceuticals Limited's (NSE:BIOFILCHEM) Price
Sep 03Getting In Cheap On Biofil Chemicals and Pharmaceuticals Limited (NSE:BIOFILCHEM) Is Unlikely
Jul 18Financial Position Analysis
Short Term Liabilities: BIOFILCHEM's short term assets (₹334.3M) exceed its short term liabilities (₹241.7M).
Long Term Liabilities: BIOFILCHEM's short term assets (₹334.3M) exceed its long term liabilities (₹3.8M).
Debt to Equity History and Analysis
Debt Level: BIOFILCHEM's net debt to equity ratio (2.9%) is considered satisfactory.
Reducing Debt: BIOFILCHEM's debt to equity ratio has reduced from 12.5% to 3.2% over the past 5 years.
Debt Coverage: BIOFILCHEM's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: BIOFILCHEM's interest payments on its debt are well covered by EBIT (33.2x coverage).